Shots: The P-III CONQUER study involves assessing of Emgality vs PBO in 462 patients in a ratio (1:1) with chronic and episodic migraine with documented prior failures on two to […]readmore
Tags : (galcanezumab-gnlm)
Shots: The P-III studies include REGAIN and EVOLVE-1 & 2 assessing Emgality vs PBO in patients with chronic and episodic migraine respectively Post-hoc analyses results: reductions in disability in chronic […]readmore
Shots: The P-III study results involve assessing of Emgality (300 mg) vs PBO in 106 patients in a ratio (1:1) with an average 17.8 vs 17.3 weekly cluster headache attacks […]readmore
Shots: The approval is based on Episodic Cluster Headache Study assessing Emgality (SC, 300 mg) vs PBO in 106 patients in ratio (1:1) with episodic cluster headache and had a […]readmore
Shots: The P-III EVOLVE-1 and EVOLVE-2 studies result involves assessing of Emgality (galcanezumab-gnlm, 120mg & 240mg) vs PBO in 1,700 patients with low (4 to<8 monthly migraine headache days) and […]readmore
Shots: Emgality’s approval is based on two P-III trials (N=425) (EVOLVE-1 and EVOLVE-2) and one P-III REGAIN trial (N=450) administering once monthly PBO vs Emgality 120 mg after an initial […]readmore